Clinical Trial Update: A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating monotherapy with BCD-264 and Darzalex in relapsed and refractory multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCD-264
• DARZALEX (daratumumab)

Snippet

Sponsor: Biocad | Conditions: Multiple Myeloma | Phase 3 | Status: RECRUITING